Justin G. Julander

TL;DR: A modified mRNA vaccine can prevent ZIKV disease and be adapted to reduce the risk of sensitizing individuals to subsequent exposure to DENV, should this become a clinically relevant concern.

TL;DR: From in vivo studies using several animal models, the pyrazinecarboxamide derivatives were found to be effective in protecting animals from death, reducing viral burden, and limiting disease manifestations, even when treatment was initiated after virus inoculation.

TL;DR: In the originally published version of the SnapShot, the unit of measure in the top left box of the image was incorrect and the name of the Australian pathologist was also incorrect; the correct name is Thomas Ashworth.

TL;DR: The adenosine nucleoside analog BCX4430 is a direct-acting antiviral drug under investigation for the treatment of serious and life-threatening infections from highly pathogenic viruses, such as the Ebola virus.

TL;DR: Clearance studies using replicon cells demonstrated that PSI-7851 was able to clear cells of HCV replicon RNA and prevent viral rebound, and cross-resistance studies using Replicon mutants conferring resistance to modified nucleoside analogs showed thatPSI- 7851 was less active against the S282T replicon mutant, whereas cells expressing a replicon containing the S96T/N142T mutation remained fully susceptible to PSI.